WO2010059668A1 - A triazolothiadiazole inhibitor of c-met protein kinase - Google Patents

A triazolothiadiazole inhibitor of c-met protein kinase Download PDF

Info

Publication number
WO2010059668A1
WO2010059668A1 PCT/US2009/064909 US2009064909W WO2010059668A1 WO 2010059668 A1 WO2010059668 A1 WO 2010059668A1 US 2009064909 W US2009064909 W US 2009064909W WO 2010059668 A1 WO2010059668 A1 WO 2010059668A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pharmaceutically acceptable
agents
compositions
met
Prior art date
Application number
PCT/US2009/064909
Other languages
English (en)
French (fr)
Inventor
David Lauffer
Pan Li
Dean Shannon
Jianglin Liang
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2743000A priority Critical patent/CA2743000A1/en
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Priority to MX2011005250A priority patent/MX2011005250A/es
Priority to CN200980146238.2A priority patent/CN102216309B/zh
Priority to ES09756109T priority patent/ES2393693T3/es
Priority to AU2009316756A priority patent/AU2009316756B2/en
Priority to NZ592825A priority patent/NZ592825A/xx
Priority to EP09756109A priority patent/EP2365977B1/en
Priority to JP2011536613A priority patent/JP5596047B2/ja
Priority to BRPI0921509A priority patent/BRPI0921509A2/pt
Priority to RU2011124894/04A priority patent/RU2011124894A/ru
Publication of WO2010059668A1 publication Critical patent/WO2010059668A1/en
Priority to ZA2011/03170A priority patent/ZA201103170B/en
Priority to IL212906A priority patent/IL212906A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to selective inhibitors of c-Met.
  • the invention also provides pharmaceutically acceptable compositions comprising a c-Met inhibitor and methods of using the compositions in the treatment of various proliferative disorders.
  • Hepatocyte growth factor also known as scatter factor
  • HGF is a multifunctional growth factor that enhances transformation and tumor development by inducing mitogenesis and cell motility. Further, HGF promotes metastasis by stimulating cell motility and invasion through various signaling pathways.
  • HGF In order to produce cellular effects, HGF must bind to its receptor, c-Met, a receptor tyrosine kinase.
  • c-Met a widely expressed heterodimeric protein comprising of a 50 kilodalton (kDa) ⁇ -subunit and a 145 kDa alpha- subunit (Maggiora et al., J.
  • c-Met is overexpressed in a significant percentage of human cancers and is amplified during the transition between primary tumors and metastasis.
  • the various cancers in which c-Met overexpression is implicated include, but are not limited to, gastric adenocarcinoma, renal cancer, small cell lung carcinoma, colorectal cancer, prostate cancer, brain cancer, liver cancer, pancreatic cancer, and breast cancer.
  • c-Met is also implicated in atherosclerosis and lung fibrosis.
  • hERG human ether-a-go-go-related gene
  • the cardiac potassium channel hERG encodes the ⁇ -subunit of the rapid delayed rectifier current 7 ⁇ r in the heart, which contributes prominently to terminal repolarization in human ventricular myocytes. See Dennis et al., Biochemical Society Transactions 35(5): 1060-1063 (2007). It has been shown that inhibition of hERG potassium channel can lead to a prolongation of the QT interval, widely considered a critical risk factor for torsades de pointes (TdP) arrhythmia. Thus, overcoming hERG binding has become a major hurdle in drug development.
  • cytochrome P450 activity is also important, particularly in therapies that may involve a combination of such agents.
  • the cytochrome P450 enzymes catalyze the oxidation of many therapeutic compounds and have an important role in the extent and duration of drug effects, by catabolizing drugs to inactive metabolites or by bio- activating prodrugs to their active forms.
  • Anti-cancer agents show a wide variation, between individuals in response, owing partly to pharmacokinetic variability. See Scipture et aL Lancet Oncology 6:780-789 (2005).
  • cytochrome P450 The most important site of metabolism mediated by cytochrome P450 is the liver, where these enzymes are ubiquitously expressed. There is also evidence that metabolism occurs within tumors and that the presence of these enzymes within tumors can have desirable or adverse effect on the efficacy of chemotherapeutic agents, depending on the isoform present and the cytotoxic agent given. Thus, developing anti-tumor agents that have favorable drug metabolism profiles is also a goal in drug discovery,
  • Met protein kinase receptor preferred compounds should have high affinity to the c-Met receptor and show functional activity as antagonists, while showing little affinity for other kinase receptors. Furthermore, it is desirable to provide c-Met receptor antagonists that have little or no hERG binding and favorable pharmacokinetic/pharmacodynamic profiles.
  • the invention also provides a crystalline form of compound 1.
  • the invention also provides pharmaceutical compositions that include compound
  • the invention provides methods of treating or lessening the severity of a proliferative disease, condition, or disorder in a patient that includes the step of administering to the patient a therapeutically effective dose of compound 1, or a pharmaceutical composition thereof.
  • the invention features the following compound:
  • the invention features a crystalline form of compound 1.
  • crystalline compound 1 is characterized by one or more of the following peaks at 2O 0 C in an X-ray diffraction pattern (2-theta scale): from 6.2 to 6.4 (e.g., about 6.3), 9.1 to 9.3 (e.g., about 9.2), 11.4 to 11.6 (e.g., about 11.5), 13.2 to 13.4 (e.g., about 13.3), 13.7 to 13.9 (e.g., about 13.8), 14.1 to 14.3 (e.g., about 14.2), 14.7 to 14.9 (e.g., about 14.8), 16.1 to 16.3 (e.g., about 16.2), 18.1 to 18.3 (e.g., about 18.2), 18.6 to 18.8 (e.g., about 18.7), and 19.7 to 19.9 (e.g., about 19.8).
  • peaks at 2O 0 C in an X-ray diffraction pattern (2-theta scale) from 6.2 to
  • the invention provides a composition comprising compound 1 or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle.
  • the amount of compound in a composition of this invention is such that is effective to measurably inhibit c-Met in a biological sample or in a patient.
  • the composition of this invention is formulated for administration to a patient in need of such composition.
  • the composition of this invention is formulated for oral administration to a patient.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable prodrugs, salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, compound 1 as otherwise described herein, or a metabolite or residue thereof.
  • pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like.
  • Pharmaceutically acceptable salts of compound 1 include those derived from suitable inorganic and organic acids and bases.
  • pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intraocular, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally, intraperitoneally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension.
  • suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
  • a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • Such materials include cocoa butter, beeswax and polyethylene glycols.
  • the pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable
  • the pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of compound 1 include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutically acceptable compositions may be formulated, e.g., as micronized suspensions in isotonic, pH adjusted sterile saline or other aqueous solution, or, preferably, as solutions in isotonic, pH adjusted sterile saline or other aqueous solution, either with or without a preservative such as benzylalkonium chloride.
  • the pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.
  • the pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • compositions of this invention are formulated for oral administration.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents,
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.
  • injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • sterilizing agents in order to prolong the effect of compound 1, it is often desirable to slow the absorption of this compound from subcutaneous or intramuscular injection.
  • Injectable depot forms are made by forming microencapsule matrices of compound 1 in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping compound 1 in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing compound 1 with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol
  • Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in micro-encapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of compound 1 include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of compound 1 to the body. Such dosage forms can be made by dissolving or dispensing compound 1 in the proper medium. Absorption enhancers can also be used to increase the flux of compound 1 across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing compound 1 in a polymer matrix or gel.
  • Compound 1 is preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of compound 1 and compositions comprising compound 1 will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • compositions should be formulated so that a dosage of from 0.01 to 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
  • compositions are formulated such that the dosage of compound 1 is from 5 to 30 mg/kg body weight/day.
  • additional therapeutic agents which are normally administered to treat or prevent that condition, may also be present in the compositions of this invention.
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated.” Examples of additional therapeutic agents are provided infra.
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the invention relates to a method of inhibiting c-
  • Met protein kinase activity in a biological sample comprising the step of contacting said biological sample with compound 1, or a composition comprising said compound.
  • biological sample means a sample outside a living organism and includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof. Inhibition of kinase activity in a biological sample is useful for a variety of purposes known to one of skill in the art. Examples of such purposes include, but are not limited to, biological specimen storage and biological assays. In one embodiment, the method of inhibiting kinase activity in a biological sample is limited to non-therapeutic methods.
  • c-Met is synonymous with “c-MET,” “cMet”, “MET”, “Met” or other designations known to one skilled in the art.
  • the invention relates to a method of inhibiting c-Met kinase activity in a patient comprising the step of administering to said patient compound
  • c-Met-mediated disease or "c-Met-mediated condition” means any disease state or other deleterious condition in which c-Met is known to play a role.
  • c-Met-mediated disease or "c-Met-mediated condition” also mean those diseases or conditions that are alleviated by treatment with a c-Met inhibitor.
  • Such conditions include, without limitation, renal, gastric, colon, brain, breast, prostate, liver, pancreatic, or lung cancer, glioblastoma, atherosclerosis, or lung fibrosis.
  • the present invention features a method treating a proliferative disorder in a patient comprising the step of administering to the patient a therapeutically effective dose of compound 1 or a composition comprising compound 1.
  • the proliferative disorder is cancer, such as, for example, renal, gastric, colon, brain, breast, liver, prostate, and lung cancer, or a glioblastoma.
  • the present invention relates to a method of treating or lessening the severity of hepatocellular carcinoma in a patient in need thereof, comprising administering to said patient compound 1 or composition thereof.
  • the proliferative disorder is polycythemia vera, essential thrombocythemia, chronic idiopathic myelofibrosis, myeloid metaplasia with myelofibrosis, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia, chronic eosinophilic leukemia, hypereosinophilic syndrome, systematic mast cell disease, atypical CML, or juvenile myelomonocytic leukemia.
  • CML chronic myeloid leukemia
  • chronic myelomonocytic leukemia chronic eosinophilic leukemia
  • hypereosinophilic syndrome systematic mast cell disease
  • atypical CML or juvenile myelomonocytic leukemia.
  • the proliferative disorder is atherosclerosis or lung fibrosis.
  • Another aspect of the present invention relates to a method of inhibiting tumor metastasis in a patient in need thereof, comprising administering to said patient compound 1 or a composition thereof.
  • additional therapeutic agents that are normally administered to treat that condition may also be present in the compositions of this invention.
  • additional therapeutic agents that are normally administered to treat a particular disease, or condition are known as "appropriate for the disease, or condition, being treated”.
  • chemotherapeutic agents or other anti-proliferative agents may be combined with compound 1 to treat proliferative diseases and cancer.
  • chemotherapeutic agents include, but are not limited to, alkylating agents, such as, for example, cyclophosphamide, lomustine, busulfan procarbazine, ifosfamide, altretamine, melphalan, estramustine phosphate, hexamethylmelamine, mechlorethamine, thiotepa, streptozocin, chlorambucil, temozolomide, dacarbazine, semustine, or carmustine; platinum agents, such as, for example, cisplatin, carboplatinum, oxaliplatin, ZD-0473 (AnorMED), spiroplatinum, lobaplatin (Aeterna), carboxyphthalatoplatinum, satraplatin (Johnson Matthey), tetraplatin BBR-34
  • alkylating agents such
  • Those additional agents may be administered separately from the compound 1- containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with compound 1 in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.
  • compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of compound 1 can be administered.
  • compositions are formulated such that the dosage of compound 1 is from 5 to 30 mg/kg body weight/day.
  • compositions that comprise an additional therapeutic agent that additional therapeutic agent and compound 1 may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent. In such compositions a dosage of between 0.01 - 100 mg/kg body weight/day of the additional therapeutic agent can be administered.
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • Compound 1, or pharmaceutical compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters.
  • an implantable medical device such as prostheses, artificial valves, vascular grafts, stents and catheters.
  • Vascular stents for example, have been used to overcome restenosis (re-narrowing of the vessel wall after injury).
  • patients using stents or other implantable devices risk clot formation or platelet activation. These unwanted effects may be prevented or mitigated by pre-coating the device with a pharmaceutically acceptable composition comprising a kinase inhibitor.
  • Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Implantable devices coated with compound 1 are another embodiment of the present invention.
  • R t (min) refers to the HPLC retention time, in minutes, associated with a compound. Unless otherwise indicated, the HPLC method utilized to obtain the reported retention time is as follows: column: Zorbax SB C18 column, 3.O x 150 mm; gradient: 10-90% acetonitrile/water (0.1% TFA), 5 minutes; flow rate: 1.0 mL/minute; and detection: 254 & 214 nm.
  • Compound 1 may be prepared by the following method, as shown in Scheme 1 and exemplified in Example 1. cone. H 9 SO 4 MeOH, reflux
  • step i) [1002] toluene, reflux (step ii)
  • step i of Scheme 1 concentrated sulfuric acid (206 mL, 3.868 mol) was added dropwise to a solution of 2-(quinolin-6-yl)acetic acid (compound 1001, 658.2 g, 3.516 mol, Okeanos Tech Co., Cat. No. OK-J-05024) in 6.5 liters of methanol. During the addition, a slight exotherm was observed. After the addition was complete, the reaction was stirred at reflux for 4 hours.
  • 2-(quinolin-6-yl)acetic acid compound 1001, 658.2 g, 3.516 mol, Okeanos Tech Co., Cat. No. OK-J-05024
  • step ii of Scheme 1 methyl 2-(quinolin-6-yl)acetate (82 g, 407.5 mmol) , paraformaldehyde (25.89 g, 862.1 mmol) , K 2 CO 3 (101.4 g, 733.5 mmol), and hexadecyl(trimethyl)ammonium hydrogen sulfate (15.55 g, 40.75 mmol) were taken up in toluene (1.6 liters) and refluxed for 2 hours until the starting material was completely consumed, as monitored by HPLC. The reaction mixture was cooled down using an ice-water bath and filtered through diatomaceous earth.
  • step iv of Scheme 1 2-(quinolin-6-yl)acrylic acid (84.5 g, 424 mmol), methanol (422 mL), and triethylamine (118 mL) was placed in a 2 liter glass cylindrical vessel under nitrogen. The solution was deoxygenated by bubbling a stream of nitrogen through the solution for 1 hour. Dichloro[(5)-(-)-2,2'-bis(diphenylphopino)-l,r-binaphthyl]ruthenium (II) (710 mg, 0.848 mmol) was added to the solution and the glass vessel was placed into a stainless steel Parr high pressure reactor and stirred 16 hours at room temperature under 1000 psi of hydrogen gas.
  • II Dichloro[(5)-(-)-2,2'-bis(diphenylphopino)-l,r-binaphthyl]ruthenium
  • ruthenium scavenger (Silicycle®-DMT, 8.78 g, 6 equiv.) added, and the mixture stirred at room temperature an additional 16 hours.
  • the mixture was filtered and the filtrate concentrated under reduced pressure to afford a brown viscous oil, which was dissolved in 170 mL of water.
  • the aqueous solution was acidified by the dropwise addition of 6 N HCl until a pH of 4-5 was achieved.
  • step v of Scheme 1 (5)-2-(quinolin-6-yl)propanoic acid (50 g, 248.5 mmol) and 1,3-diaminothiourea (29.02 g, 273.4 mmol) were suspended in a mixture of tetramethylene sulfone (sulfolane, 38 mL) and water (57 mL). Methane sulfonic acid (35.5 ml, 546.7 mmol) was added to the mixture, whereupon all solids dissolved. The reaction temperature was slowly increased to 90 0 C and the reaction was heated at 90 0 C for 40 hours, at which time a 68% conversion of starting material to product was observed by HPLC analysis.
  • tetramethylene sulfone sulfolane, 38 mL
  • Methane sulfonic acid 35.5 ml, 546.7 mmol
  • reaction mixture was cooled in an ice bath and water (75 mL) was added, followed by the careful addition of saturated sodium bicarbonate (500 mL) until a pH 8 was achieved.
  • saturated sodium bicarbonate 500 mL
  • the resulting fine purple precipitate was collected by vacuum filtration, washed with water, saturated sodium bicarbonate, water, and methyl t-butyl ether, respectively.
  • the product was 92% pure by 1 H NMR analysis, with the major impurities being compound 1004 and sulfolane.
  • Chiral HPLC analysis showed 92% ee (ChiralPak® AD-H, 70% z-propanol/hexanes; retention time: 4.98 min for S-enantiomer, 12.33 min for i?-enantiomer).
  • the product was used as is in the next step without further purification.
  • Compound 1004 could be recovered from the aqueous filtrate by adjusting its pH to 5, collecting any precipitated material, and extracting the remaining filtrate with ethyl acetate (3 times). The combined organics were dried over anhydrous sodium sulfate, filtered, and evaporated under reduced pressure to afford a dark oil, which was taken up in 90 mL of ethyl acetate and heated to reflux for 0.5 hour. Cooling resulted in additional precipitate which, when combined with the previously collected precipitate, resulted in the recovery of compound 1004 as white solid (7 g).
  • the aqueous solution was treated with saturated sodium bicarbonate (3.2 liters) until a p ⁇ of 7 was achieved.
  • the resulting oil was decanted off and dissolved in a small amount of methanol, with the remaining aqueous layer extracted with dichloromethane (4 times).
  • the combined organic extracts and the methanol solution of the oil were combined and washed with saturated sodium bicarbonate, water, and brine, respectively.
  • the organics were dried over anhydrous MgSO 4 , filtered, and evaporated under reduced pressure to afford the crude product as a thick brown oil.
  • the product was purified by silica gel chromatography, eluting with a gradient of dichloromethane to 5% methanol in dichloromethane.
  • Compound 1 was screened for its ability to inhibit c-Met kinase using a standard radiometric assay. Briefly, in this kinase assay the transfer of the terminal 33 P-phosphate in 33 P- ATP to substrate polyE4Y is interrogated. The assay was carried out in 96-well plates to a final volume of 100 ⁇ L per well containing 0.5 nM c-Met, 100 mM HEPES (pH 7.5), 10 mM MgCl 2 , 25 mM NaCl, 0.01% BSA, 1 mM DTT, 0.5 mg/mL polyE4Y, and 35 ⁇ M ATP.
  • a standard radiometric assay the transfer of the terminal 33 P-phosphate in 33 P- ATP to substrate polyE4Y is interrogated. The assay was carried out in 96-well plates to a final volume of 100 ⁇ L per well containing 0.5 nM c-Met, 100 mM HEPES (pH 7.5), 10
  • Compound 1 was also screened for their ability to inhibit the Luciferase-induced signal in an engineered Snu5 cell line.
  • Snu5 obtained from American Type Culture Collection (Catalog number CRL-5973)
  • pCLPCX which contains a genetic construct consisting of 6xAPl promoter response elements and a luciferase gene having a C-terminal PEST sequence (proteolytic signal from mouse ornithine decarboxylase, which reduces the half- life of the luciferase).
  • the constitutively active c-Met activates cellular pathways (principally MAP kinase), resulting in AP-I -induced transcription of luciferase-PEST and translation into the final product, the activity of which is quantifiable as a chemiluminescent readout upon the addition of luciferin (Steady-Glo from Promega.). Residual luminescence is strongly correlated to the inhibition of c-Met.
  • a stable cell line was obtained by selecting the new cell line (Snu5 -API -Luc-Pest) with puromycin.
  • the cells were grown in complete media [Iscove's media (Invitrogen) containing 10% fetal bovine serum (FBS, Hyclone) and penicillin/gentamycin (Invitrogen)].
  • Compounds of the invention were dissolved in DMSO to make 10 mM initial stock solutions. Serial dilutions in DMSO were then made and transferred to complete medium to make a 10x solution.
  • the Snu5-APl -Luc-Pest cells were counted and diluted to 200,000-cells/mL solution.
  • the cells (90 ⁇ L) were added to each well in a 96-well black with clear bottom plate (Costar). Then 10 ⁇ L of the 10x compound solution was added to the cells in triplicate.
  • the plates were incubated in a 37°C/5% CO 2 incubator. After 6 hours, 50 ⁇ L of the Steady-Glo reagent (Promega) was added to each well and placed on a plate shaker for 5 minutes to ensure that the cells were completely lysed. The plate was read on a 1450 Microbeta Liquid Scintillation and Luminescence Counter (Perkin-Elmer). The IC50 was calculated using a 4-parameter fit using the graphing software Prism (GraphPad). The IC 50 for compound 1 is 0.023 +/- 0.012 ⁇ M.
  • the cardiac potassium channel, hERG is responsible for a rapid delayed rectifier current (/&) in the human ventricle. Inhibition of /& is the most common cause of cardiac action potential prolongation by non-cardiac drugs. Increase action potential duration causes prolongation of the QT interval that has been associated with a dangerous ventricular arrhythmia, torsade de pointes.
  • hERG binding was determined using a hERG block comparative study to evaluate the effect of a given test compound on cloned hERG channels expressed in mammalian cells.
  • Test compounds were delivered in HEPE S -buffered physiological saline (HB-PS)
  • DMSO dimethyl sulfoxide
  • the pipette solution for whole cell recordings included potassium aspartate (130 mM), MgCl 2 (5 mM), EGTA (5 mM), ATP (4 mM), and HEPES (10 mM) at a pH adjusted to 7.2 with KOH.
  • Onset and steady state block of hERG current due to the test compound were measured using a pulse pattern with fixed amplitudes (depolarization: +20 mV for 2 seconds; repolarization: -50 mV for 2 seconds), repeated at 10 second intervals, from a holding potential of -80 mV. Peak tail current was measured during the 2 second step to -50 mV.
  • a steady state was maintained for at least 30 seconds before applying the test compound or positive control compound.
  • [Cone] is the concentration of each compound solution tested, IC 50 is the concentration of the test compound producing half-maximal inhibition, N is the Hill coefficient, and % inhibition is the percentage of hERG potassium current inhibited at each compound concentration.
  • IC 50 is the concentration of the test compound producing half-maximal inhibition
  • N is the Hill coefficient
  • % inhibition is the percentage of hERG potassium current inhibited at each compound concentration.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2009/064909 2008-11-19 2009-11-18 A triazolothiadiazole inhibitor of c-met protein kinase WO2010059668A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
NZ592825A NZ592825A (en) 2008-11-19 2009-11-18 A triazolothiadiazole inhibitor of c-met protein kinase
MX2011005250A MX2011005250A (es) 2008-11-19 2009-11-18 Inhibidores de triazolotiadiazol de cinasa de proteina c-met.
CN200980146238.2A CN102216309B (zh) 2008-11-19 2009-11-18 C-met蛋白激酶的三唑并噻二唑抑制剂
ES09756109T ES2393693T3 (es) 2008-11-19 2009-11-18 Un derivado de triazolotiadiazol como inhibidor de la proteína-quinasa c-Met
AU2009316756A AU2009316756B2 (en) 2008-11-19 2009-11-18 A triazolothiadiazole inhibitor of c-Met protein kinase
CA2743000A CA2743000A1 (en) 2008-11-19 2009-11-18 A triazolothiadiazole inhibitor of c-met protein kinase
EP09756109A EP2365977B1 (en) 2008-11-19 2009-11-18 A triazolothiadiazole derivative as inhibitor of c-met protein kinase
RU2011124894/04A RU2011124894A (ru) 2008-11-19 2009-11-18 Триазолотиадиазоловый ингибитор протеинкиназы с-мет
BRPI0921509A BRPI0921509A2 (pt) 2008-11-19 2009-11-18 inibidor triazolotiadiazol de proteína quinase c-met
JP2011536613A JP5596047B2 (ja) 2008-11-19 2009-11-18 ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
ZA2011/03170A ZA201103170B (en) 2008-11-19 2011-04-29 A triazolothiadiazole inhibitor of c-met protein kinase
IL212906A IL212906A0 (en) 2008-11-19 2011-05-16 Triazolothiadiazole inhibitor compounds, compositions comprising the same and uses thereore

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11603308P 2008-11-19 2008-11-19
US61/116,033 2008-11-19

Publications (1)

Publication Number Publication Date
WO2010059668A1 true WO2010059668A1 (en) 2010-05-27

Family

ID=42027848

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/064909 WO2010059668A1 (en) 2008-11-19 2009-11-18 A triazolothiadiazole inhibitor of c-met protein kinase

Country Status (18)

Country Link
US (3) US8217056B2 (ja)
EP (1) EP2365977B1 (ja)
JP (1) JP5596047B2 (ja)
KR (1) KR20110094285A (ja)
CN (1) CN102216309B (ja)
AR (1) AR074379A1 (ja)
AU (1) AU2009316756B2 (ja)
BR (1) BRPI0921509A2 (ja)
CA (1) CA2743000A1 (ja)
CL (1) CL2011001152A1 (ja)
ES (1) ES2393693T3 (ja)
IL (1) IL212906A0 (ja)
MX (1) MX2011005250A (ja)
NZ (1) NZ592825A (ja)
RU (1) RU2011124894A (ja)
TW (1) TW201024309A (ja)
WO (1) WO2010059668A1 (ja)
ZA (1) ZA201103170B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138673A1 (en) * 2009-05-28 2010-12-02 Vertex Pharmaceuticals Incorporated Inhibitors of c-met protein kinase
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166008A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
RU2011124894A (ru) * 2008-11-19 2012-12-27 Вертекс Фармасьютикалз Инкорпорейтед Триазолотиадиазоловый ингибитор протеинкиназы с-мет
ES2433090T3 (es) * 2009-05-28 2013-12-09 Vertex Pharmaceuticals Incorporated Inhibidores a base de aminopirazol triazolotiadiazol de la proteína cinasa c-met
MX2011012522A (es) * 2009-05-28 2012-02-08 Vertex Pharma Inhibidores de pirazol sustituido de proteina cinasa c-met.
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
JP7268957B2 (ja) 2017-12-01 2023-05-08 英典 佐藤 振動発生装置、及び振動発生システム
CN109897054B (zh) * 2017-12-08 2021-12-10 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
WO2008144767A1 (en) * 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011124894A (ru) * 2008-11-19 2012-12-27 Вертекс Фармасьютикалз Инкорпорейтед Триазолотиадиазоловый ингибитор протеинкиназы с-мет

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
WO2008144767A1 (en) * 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia ofPharmaceutical Technology", 1988, MARCEL DEKKER
"Handbook of Chemistry and Physics", 1994
"March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS
"Remington: The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS
"The ACS Style Guide: A Manual for Authors and Editors", 1997, AMERICAN CHEMICAL SOCIETY
BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SCIPTURE ET AL., LANCET ONCOLOGY, vol. 6, 2005, pages 780 - 789
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138673A1 (en) * 2009-05-28 2010-12-02 Vertex Pharmaceuticals Incorporated Inhibitors of c-met protein kinase
US8263776B2 (en) 2009-05-28 2012-09-11 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met protein kinase
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Also Published As

Publication number Publication date
EP2365977B1 (en) 2012-10-03
US8217056B2 (en) 2012-07-10
NZ592825A (en) 2013-01-25
US8343998B2 (en) 2013-01-01
KR20110094285A (ko) 2011-08-23
US20100234423A1 (en) 2010-09-16
EP2365977A1 (en) 2011-09-21
US20110207774A1 (en) 2011-08-25
IL212906A0 (en) 2011-07-31
CA2743000A1 (en) 2010-05-27
CN102216309B (zh) 2014-05-07
ZA201103170B (en) 2012-08-29
ES2393693T3 (es) 2012-12-27
BRPI0921509A2 (pt) 2016-03-08
TW201024309A (en) 2010-07-01
JP5596047B2 (ja) 2014-09-24
MX2011005250A (es) 2011-07-29
AU2009316756A1 (en) 2010-05-27
CL2011001152A1 (es) 2012-02-24
JP2012509279A (ja) 2012-04-19
RU2011124894A (ru) 2012-12-27
AR074379A1 (es) 2011-01-12
US20110301195A1 (en) 2011-12-08
AU2009316756B2 (en) 2016-02-25
CN102216309A (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
EP2365977B1 (en) A triazolothiadiazole derivative as inhibitor of c-met protein kinase
US8269013B2 (en) Substituted pyrazole inhibitors of c-Met protein kinase
US8263776B2 (en) Inhibitors of c-Met protein kinase
EP2435443B1 (en) Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
US8263777B2 (en) Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980146238.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09756109

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1831/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2743000

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009316756

Country of ref document: AU

Ref document number: 592825

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 212906

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2011536613

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20117011277

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011001152

Country of ref document: CL

Ref document number: MX/A/2011/005250

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009316756

Country of ref document: AU

Date of ref document: 20091118

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009756109

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: A201107660

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2011124894

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0921509

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110518